Literature DB >> 26609206

Afrezza (Insulin Human) Inhalation Powder: A New Inhaled Insulin for the Management Of Type-1 or Type-2 Diabetes Mellitus.

Tamara Goldberg, Elaine Wong.   

Abstract

Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus.

Entities:  

Year:  2015        PMID： 26609206      PMCID： PMC4634344     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  15 in total

Review 1.  Alternative delivery routes: inhaled insulin.

Authors:  L Heinemann
Journal:  Diabetes Nutr Metab       Date:  2002-12

2.  Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine.

Authors:  Elizabeth Potocka; James P Cassidy; Pamela Haworth; Douglas Heuman; Sjoerd van Marle; Robert A Baughman
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

3.  Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.

Authors:  P Raskin; S Heller; M Honka; P-C Chang; A H Boss; P C Richardson; N Amin
Journal:  Diabetes Obes Metab       Date:  2011-11-03       Impact factor: 6.577

4.  Progression of type 2 diabetes and insulin initiation.

Authors:  Arturo R Rolla
Journal:  J Natl Med Assoc       Date:  2011-03       Impact factor: 1.798

5.  Technosphere insulin: defining the role of Technosphere particles at the cellular level.

Authors:  Robert Angelo; Kathleen Rousseau; Marshall Grant; Andrea Leone-Bay; Peter Richardson
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

6.  Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.

Authors:  Julio Rosenstock; Daniel L Lorber; Luigi Gnudi; Campbell P Howard; David W Bilheimer; P-C Chang; Richard E Petrucci; Anders H Boss; Peter C Richardson
Journal:  Lancet       Date:  2010-06-26       Impact factor: 79.321

7.  Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease.

Authors:  Elizabeth Potocka; Nikhil Amin; James Cassidy; Sherwyn L Schwartz; Madison Gray; Peter C Richardson; Robert A Baughman
Journal:  Curr Med Res Opin       Date:  2010-10       Impact factor: 2.580

Review 8.  A review of inhaled technosphere insulin.

Authors:  Joshua J Neumiller; R Keith Campbell; Lindy D Wood
Journal:  Ann Pharmacother       Date:  2010-06-01       Impact factor: 3.154

Review 9.  Inhaled insulin--does it become reality?

Authors:  R Siekmeier; G Scheuch
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

10.  Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.

Authors:  K Rave; E Potocka; L Heinemann; T Heise; A H Boss; M Marino; D Costello; R Chen
Journal:  Diabetes Obes Metab       Date:  2009-05-19       Impact factor: 6.577
View more
  4 in total

Review 1.  Inhaled Insulin - Current Direction of Insulin Research.

Authors:  Rashmi Ranjan Mohanty; Smita Das
Journal:  J Clin Diagn Res       Date:  2017-04-01

Review 2.  Insulin: evolution of insulin formulations and their application in clinical practice over 100 years.

Authors:  Geremia B Bolli; Alice Y Y Cheng; David R Owens
Journal:  Acta Diabetol       Date:  2022-07-19       Impact factor: 4.087

3.  Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.

Authors:  Juan M Galdopórpora; Camila Martinena; Ezequiel Bernabeu; Jennifer Riedel; Lucia Palmas; Ines Castangia; Maria Letizia Manca; Mariana Garcés; Juan Lázaro-Martinez; Maria Jimena Salgueiro; Pablo Evelson; Nancy Liliana Tateosian; Diego Andres Chiappetta; Marcela Analia Moretton
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

Review 4.  Place of technosphere inhaled insulin in treatment of diabetes.

Authors:  Nasser Mikhail
Journal:  World J Diabetes       Date:  2016-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.